Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed newly diagnosed non-small cell bronchogenic carcinoma~  * Squamous cell~ * Adenocarcinoma~ * Large cell undifferentiated~ * Bronchoalveolar~ * Non-small cell carcinoma not otherwise stated~* Unresectable stage IIIA~  * Mediastinal lymph node enlargement of at least 1 cm but less than 2 cm on computed tomography (CT) scans must have mediastinotomy or thoracoscopy to rule out resectability~OR~* Stage IIIB disease without significant pleural effusion~  * Seen on CT scan only (not seen on chest x-ray) or does not reaccumulate after 1 thoracentesis and is cytologically negative~ * Metastases to contralateral, mediastinal, or supraclavicular nodes allowed~* Bidimensionally measurable or evaluable disease~* 18 and over~* ECOG performance status 0-1~* Adequate hematopoietic, hepatic, and renal function obtained \<=4 weeks prior to registration:~  * Platelet count at least 100,000/mm\^3~ * White Blood Cell (WBC) count at least 4,000/mm\^3 OR absolute neutrophil count at least 2,000/mm\^3~ * Bilirubin normal~ * Serum glutamic oxaloacetic transaminase (SGOT) no greater than 2.5 times upper limit of normal~ * Creatinine no greater than 1.5 mg/dL OR creatinine clearance at least 60 mL/min~* Fertile patients must use 2 methods of effective contraception for 4 weeks prior to, during, and for 4 weeks after study therapy~* Concurrent filgrastim (G-CSF) allowed for persistent neutropenia~Exclusion Criteria:~* Positive pregnancy test,pregnant or nursing~* Uncontrolled high blood pressure, unstable angina, congestive heart failure, or myocardial infarction within the prior year~* Serious cardiac arrhythmias requiring medication~* Prior radiotherapy to only area of measurable or active tumor~* Less than 5 years since prior chemotherapy~* Other active malignancies~* Serious uncontrolled active infection~* Evidence of greater than grade 1 neuropathy by history or physical examination~* History of seizure disorders~* Contraindication to daily low-dose (81 mg/day) aspirin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Paclitaxel + Carboplatin + RT) (Type: ACTIVE_COMPARATOR): Induction chemotherapy dosing: Paclitaxel, 225 mg/m² (3 hour infusion) Day 1. Carboplatin, area under the plasma drug concentration versus time curve (AUC) =6.0, 15-30 min IV infusion immediately following paclitaxel, Day 1~Concurrent chemotherapy / radiotherapy dosing: Paclitaxel, 45 mg/m2, administered weekly during radiotherapy over one hour. Carboplatin, AUC=2, 15- 30 minutes IV infusion immediately following paclitaxel; administered weekly during radiotherapy~Radiation therapy started between days 43-50 from day 1 of cycle 1. The primary tumor and areas of known nodal disease received 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks to the post chemotherapy tumor volume as seen on computed tomography (CT). The initial 50 Gy was delivered to target volume (TV). The final 10 Gy was delivered to a reduced volume targeting defined by TV
- Arm B (Paclitaxel + Carboplatin + RT+ Thalidomide) (Type: EXPERIMENTAL): paclitaxel, carboplatin, and radiotherapy are same as those in Arm A.~thalidomide: Induction chemotherapy dosing, oral daily, starting Day 1 for 24 months or until disease progression. Concurrent chemotherapy / radiotherapy dosing, oral daily, begin with 200 mg thalidomide as a single dose at bedtime. The dose is then increased by 100 mg every week as tolerated up to a total dose of 1000 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).